Mark Socinski, MD, shares insight on the role of atezolizumab in treating nondriver non–small cell lung cancer given data from the OAK clinical trial, particularly in regard to squamous cell histology.

For more resources and information regarding anticancer targeted therapies: [ Ссылка ]

свернуть